Adrixetinib
Adrixetinib (Q702) is an Axl/Mer/CSF1R protein tyrosine kinase inhibitor with antineoplastic activity[1][2].
Product Specifications
CAS Number
[2394874-66-7]
Product Name Alternative
Q702
UNSPSC
12352005
Target
C-Fms; TAM Receptor
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/adrixetinib.html
Purity
99.51
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(C1=NN(CCC)C=C1OCC(F)(F)F)NC2=NC=C(C=C2)OC3=C4C=C(OC)C(OC)=CC4=NC=C3
Molecular Formula
C25H24F3N5O5
Molecular Weight
531.48
References & Citations
[1]WHO Drug Informat ion - World Health Organization (WHO) .|[2]Nam Kiyean, et al. Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R and their preparation: World Intellectual Property Organization, WO2019229251. 2019-12-05.|[3]WHO Drug Information-World Health Organization (WHO) .
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1086153-01 1 mg (E-Coli)
Recombinant Avahi cleesei NADH-ubiquinone oxidoreductase chain 4 (MT-ND4), partial
Ask
View Details 
MBS1086153-02 1 mg (Yeast)
Recombinant Avahi cleesei NADH-ubiquinone oxidoreductase chain 4 (MT-ND4), partial
Ask
View Details